<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">16491721</PMID>
<DateCompleted>
<Year>2006</Year>
<Month>03</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0191-3913</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>43</Volume>
<Issue>1</Issue>
<PubDate>
<MedlineDate>2006 Jan-Feb</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Journal of pediatric ophthalmology and strabismus</Title>
<ISOAbbreviation>J Pediatr Ophthalmol Strabismus</ISOAbbreviation>
</Journal>
<ArticleTitle>Controlling contagious bacterial conjunctivitis.</ArticleTitle>
<Pagination>
<MedlinePgn>19-26</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent outbreaks (epidemics) of Streptococcus pneumoniae conjunctivitis, involving hundreds of patients, underscore the importance of following recommended guidelines to minimize disease transmission. These include the use of antimicrobial agents capable of minimizing patients' symptoms and the duration of the infectious period when disease can be transmitted to others.</AbstractText>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To compare the amount of time required forvarious antibiotic solutions to kill S. pneumoniae, a common cause of bacterial conjunctivitis.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Isolates of S. pneumoniae from three patients were exposed to selected ophthalmic antibiotic products: moxifloxacin 0.5%, tobramycin 0.3%, gentamicin 0.3%, and polymyxin B 10,000 IU-trimethoprim 1.0%. The products were diluted 1:100 and 1:1000 for testing. At 15, 30, 60, 120, and 180 minutes after exposure, aliquots of broth were withdrawn, the cells were separated and cultured, and the viable cell count was determined.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Moxifloxacin killed actively growing S. pneumoniae faster and to a greater extent than did the other three antibiotic products when tested at concentrations corresponding to tear film concentrations 5 to 10 minutes and 30 to 60 minutes after instillation of the products.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Moxifloxacin killed S. pneumoniae in vitro faster than did the other antibiotics. Consequently, its use should complement other generally accepted measures for minimizing patients' symptoms and limiting the contagiousness of bacterial conjunctivitis. Also, this is consistent with the recommendations of other investigators to prescribe the most recent generation of fluoroquinolone antibiotics for the specific purpose of limiting the spread of bacterial resistance.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lichtenstein</LastName>
<ForeName>Steven J</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>University of Illinois at Peoria, University of Illinois at Chicago, Chicago, Illinois, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dorfman</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kennedy</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stroman</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Pediatr Ophthalmol Strabismus</MedlineTA>
<NlmUniqueID>7901143</NlmUniqueID>
<ISSNLinking>0191-3913</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001372">Aza Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D024841">Fluoroquinolones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005839">Gentamicins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009883">Ophthalmic Solutions</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011804">Quinolines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>J2VZ07J96K</RegistryNumber>
<NameOfSubstance UI="D011112">Polymyxin B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>U188XYD42P</RegistryNumber>
<NameOfSubstance UI="D000077266">Moxifloxacin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>VZ8RRZ51VK</RegistryNumber>
<NameOfSubstance UI="D014031">Tobramycin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>J Pediatr Ophthalmol Strabismus. 2006 Jan-Feb;43(1):13</RefSource>
<PMID Version="1">16491719</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000900">Anti-Bacterial Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001372">Aza Compounds</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015169">Colony Count, Microbial</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003234">Conjunctivitis, Bacterial</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000635">transmission</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018562">Disease Transmission, Infectious</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D024841">Fluoroquinolones</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005839">Gentamicins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D066298">In Vitro Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000077266">Moxifloxacin</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009883">Ophthalmic Solutions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011008">Pneumococcal Infections</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000635">transmission</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011112">Polymyxin B</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011804">Quinolines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013296">Streptococcus pneumoniae</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014031">Tobramycin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2006</Year>
<Month>2</Month>
<Day>24</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2006</Year>
<Month>3</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2006</Year>
<Month>2</Month>
<Day>24</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">16491721</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>